Search PubMed⌕ Search

Biomedical subjects

C C Chin

Publications and source records attributed to C C Chin.

At least 37 records · Page 2Linked to original sources
PubMed1986

Human placental estradiol 17 beta-dehydrogenase: sequence of a histidine-bearing peptide in the catalytic region.

The amino acid sequence of an octapeptide from the catalytic site of human placental estradiol 17 beta-dehydrogenase (EC 1.1.1.62) was established by affinity-labeling techniques. The enzyme was inactivated separately by 12 beta-hydroxy-4-estrene-3,17-dione 12-(bromo[2-14C]acetate) and 3-methoxyestriol 16-(bromo[2-14C]acetate) at pH 6.3. The inactivations, in both cases, followed pseudo-first-order kinetics with half-times for the 12 beta and 16 alpha derivatives being 192 and 68 h, respectively. Both derivatives are known substrates that inactivate in a time-dependent, irreversible manner and that modify cysteine residues to form (carboxymethyl)cysteine and histidine residues to form either N tau- or N pi-(carboxymethyl)histidine. The inactivated enzyme samples were separately reduced, carboxymethylated, and digested with trypsin. The tryptic digests were applied to Sephadex G-50 and the radioactive N tau- and N phi-(carboxymethyl)histidine-bearing peptides identified. The peptides were further purified by cation-exchange chromatography and gel filtration. Final purification was achieved by HPLC prior to sequencing. It was determined that both steroid derivatives modified either of the two histidine residues in the peptide Thr-Asp-Ile-His-Thr-Phe-His-Arg. These histidines are different from a histidine that was previously shown to be alkylated by estrone 3-(bromoacetate) and that was presumed to proximate the A ring of the bound steroid. It is concluded that the two histidine residues identified in the present study proximate the D ring of the steroid as it binds at the active site and may participate in the hydrogen transfer effected by human placental estradiol 17 beta-dehydrogenase.

17-Hydroxysteroid Dehydrogenases↗
PubMed1985

Overproduction and nucleotide sequence of the respiratory D-lactate dehydrogenase of Escherichia coli.

Recombinant DNA plasmids containing the gene for the membrane-bound D-lactate dehydrogenase (D-LDH) of Escherichia coli linked to the promoter PL from lambda were constructed. After induction, the levels of D-LDH were elevated 300-fold over that of the wild type and amounted to 35% of the total cellular protein. The nucleotide sequence of the D-LDH gene was determined and shown to agree with the amino acid composition and the amino-terminal sequence of the purified enzyme. Removal of the amino-terminal formyl-Met from D-LDH was not inhibited in cells which contained these high levels of D-LDH.

Amino Acid Sequence↗
PubMed1983

Human placental estradiol 17 beta-dehydrogenase. Identification of a single histidine residue affinity-labeled by both 3-bromoacetoxyestrone and 12 beta-bromoacetoxy-4-estrene-3,17-dione.

Human placental estradiol 17 beta-dehydrogenase (EC 1.1.1.62) was affinity-labeled at pH 6.3 by 3-bromo[2'-14C]acetoxyestrone and 12 beta-bromo-[2'-14C] acetoxy-4-estrene-3,17-dione (both are substrates) in separate incubations. The affinity-alkylated enzyme samples were then treated separately as described below. Amino acid compositions of both samples revealed radioactive 3-carboxymethylhistidine. Tryptic digests of each sample were prepared, applied to Sephadex G-50, and 3-carboxymethylhistidine-bearing fractions identified. These peptides were further purified by cation exchange chromatography, gel filtration, and paper electrophoresis. The purified, 3-carboxymethylhistidine-bearing peptides labeled by the two steroids had identical electrophoretic mobilities at pH 6.5, 3.5, and 1.9. The amino acid sequence of the radioactive peptide alkylated by 3-bromo[2'-14C]acetoxyesterone was determined as: Leu-Ala-3-[14C]CmHis-Ser-Lys. The smaller quantity of peptide obtained from the inactivation with 12 beta-bromo[2'-14C]acetoxy-4-estrene-3,17-dione precluded the determination of its complete sequence. However, the first 3 residues were found to be Leu-Ala-3-[14C]CmHis and the amino acid composition showed that serine and lysine were also present. It is concluded that the steroid-binding site of human placental estradiol 17 beta-dehydrogenase contains a histidine residue which proximates the upper A-ring region of the steroid as it undergoes the reversible binding step.

17-Hydroxysteroid Dehydrogenases↗
PubMed1983

The amino acid sequence of Escherichia coli cyanase.

The amino acid sequence of the enzyme cyanase (cyanate hydrolase) from Escherichia coli has been determined by automatic Edman degradation of the intact protein and of its component peptides. The primary peptides used in the sequencing were produced by cyanogen bromide cleavage at the methionine residues, yielding 4 peptides plus free homoserine from the NH2-terminal methionine, and by trypsin cleavage at the 7 arginine residues after acetylation of the lysines. Secondary peptides required for overlaps and COOH-terminal sequences were produced by chymotrypsin or clostripain cleavage of some of the larger peptides. The complete sequence of the cyanase subunit consists of 156 amino acid residues (Mr 16,350). Based on the observation that the cysteine-containing peptide is obtained as a disulfide-linked dimer, it is proposed that the covalent structure of cyanase is made up of two subunits linked by a disulfide bond between the single cystine residue in each subunit. The native enzyme (Mr 150,000) then appears to be a complex of four or five such subunit dimers.

Amino Acid Sequence↗
PubMed1983

CNS manifestations of epidemic hemorrhagic fever. An advanced manifestation of disease associated with poor prognosis.

The records of 134 patients with the clinical diagnosis of epidemic hemorrhagic fever (EHF) were evaluated. The conditions of 74 patients could be categorized as "serious" based on hemorrhagic complications and magnitude of proteinuria, BP abnormality, and pyrexia. Forty-six of these patients with a serious condition had one or more CNS abnormalities. Common manifestations included confusion, meningismus, and convulsions. Whereas abnormality in fever could not be related to CNS abnormality, BP disturbance, acidosis, and azotemia were significantly more common among patients with CNS disease. Fourteen percent of the patients in this study died, and all of them had CNS disturbance; mortality among patients with CNS disturbance was 41%. These results suggest that the CNS manifestations of EHF are multifactorial in cause and they identify a subset of patients with an advanced stage of disease and a grave prognosis.

Central Nervous System Diseases↗
PubMed1982

Spatial relationship of steroid and cofactor at the active site of human placental estradiol 17 beta-dehydrogenase.

Two affinity-labeling steroids (2-bromo[2'-14C]acetamidoestrone methyl ether and 16 alpha-bromo[2'-14C]acetoxyestradiol 3-methyl ether) which bear their reagent groups on the A- and D-ring of the molecule, respectively, and which are both substrates, have been used to elucidate spatial relationships of steroid and cofactor as they undergo the reversible binding step at the active site of human placental estradiol 17 beta-dehydrogenase. The 2-derivative alkylates its evolutive cofactor (NADH) in the presence of the enzyme but not in the absence of enzyme. The rate of cofactor alkylation increases with increasing quantities of enzyme and is slowed by estrone which competes for the enzyme-active site. To the contrary, the 16 alpha-derivative does not detectably alkylate its evolutive cofactor (NAD+). The product of cofactor alkylation by 2-bromoacetamidoestrone methyl ether was treated to effect hydrolytic removal of the adenine moiety from the remainder of the cofactor, reduction of the steroid 17-keto group, and crystallization. The final crystalline product has been identified as 2-[2'-6N-adenyl]acetamidoestradiol 3-methyl ether (IUPAC name: N-(3-methoxy-17 beta-hydroxy-1,3,5(10)-estratrien-2-yl)-2-(purin-6-ylamino) acetamide) by ultraviolet, infrared, NMR, and mass spectral analysis.

17-Hydroxysteroid Dehydrogenases↗
PubMed1981

The amino acid sequence of yeast enolase. Preparation and characterization of peptides produced by chemical and enzymatic fragmentation.

Yeast enolase was subjected to chemical and enzymatic fragmentation, and the individual peptides produced were isolated by gel filtration and ion exchange chromatography. The chemical fragmentation was achieved by cleavage at the single cysteine residue with 2-nitro-5-thiocyanobenzoic acid, or at the 5 methionine residues with cyanogen bromide. The assignment of the two 2-nitro-5-thiocyanobenzoic acid fragments to the NH2-terminal or COOH-terminal regions (designated C1 and C2, respectively) of the enolase subunit could be done unequivocally on the basis of NH2-terminal and COOH-terminal analysis, and the same was the case for the NH2-terminal and COOH-terminal cyanogen bromide peptides (designated M1 and M6, respectively). From a comparison of the CNBr peptides from enolase with those from Fragment C1, the identity of methionine peptides M4, of which only the NH2-terminal half is present in C1, and M5, which along with M6 is missing in C1, could also be established. The major enzymatic fragmentation was achieved by tryptic cleavage at the 14 arginine residues after acetylation of the lysine residues. Based on overlaps with methionine peptides, most of the arginine peptides could be ordered in proper sequence during the early phases of the work. Because of the size of several of the primary fragments, secondary cleavages were required for optimal sequencing data. These secondary cleavages were accomplished by digestion with Staphylococcus aureus protease, or by tryptic cleavage at cysteine after aminoethylation.

Amino Acid Sequence↗
PubMed1981

The amino acid sequence of yeast enolase.

Automatic sequencing of yeast enolase and of its chemically and enzymatically produced peptide fragments has established the sequence of 416 of the 436 residues in the enolase subunits. The missing segments have been provided from results from sequencing the DNA of the yeast enolase genes (Holland, M. J., Holland, J. P., Thill, G. P., and Jackson, K. A. (1981) J. Biol. Chem. 256, 1385-1395). The reported enolase sequence thus represents the results of two completely independent studies, which yielded identical results for 404 of the 436 residues, and which on re-examination are consistent with the reported sequence in all but nine positions. The availability of the entire yeast enolase sequence has permitted a reassessment of structure-function parameters available for the enzyme, and some implications of the sequence information on the secondary, tertiary, and quarternary structure and on the active site components of yeast enolase have been summarized and discussed.

Amino Acid Sequence↗
PubMed1980

Synthesis of 2-bromoacetamidoestrone methyl ether and study of the steroid-binding site of human placental estradiol 17 beta-dehydrogenase.

To characterize further the active site of human placental estradiol 17 beta-dehydrogenase (EC 1.1.1.62), we have synthesized 2-bromoacetamidoestrone methyl ether. The affinity-labeling steroid is a substrate for the homogeneous enzyme. It inactivates the enzyme in a time-dependent, irreversible manner which follows pseudo-first order kinetics. Further, inactivation conducted with varying steroid concentration displays saturation kinetics. When 1.7 x 10(-6) M enzyme is inactivated by 2.6 x 10(-4) M 2-bromoacetamidoestrone methyl ether, the presence of an equimolar concentration of estradiol or 5.2 x 10(-4) M concentrations of NAD+, NADP+, or NADPH markedly slow the rate of inactivation. Bromoacetate (2.6 x 10(-4) M) does not inactivate the enzyme. After inactivation with 2-bromo[2'-14C]acetamidoestrone methyl ether, amino acid analysis reveals carboxymethylated derivatives of cysteine, histidine, and lysine containing 65, 25, and 8%, respectively, of the total incorporated carboxymethyl groups. The presence of estradiol, NADP+, or NADPH clearly inhibits alkylation of cysteinyl and histidyl residues and slows the rate of enzyme inactivation. Protection of these residues by both estradiol and NADPH suggests that they may actually be in the cofactor region of the active site, that this region is close to the steroid A-ring, and that binding of cofactor, by physical interposition, denies the reagent-bearing steroid access to these residues.

17-Hydroxysteroid Dehydrogenases↗
PubMed1977

Structure of the steroid-binding site of human placental estradiol-17beta-dehydrogenase.

We recently demonstrated that human placental estradiol-17beta-dehydrogenase possesses a histidyl residue in the catalytic region of the active site by affinity-labeling studies with 16alpha-bromoacetoxyestradiol-3-methyl ether. We now report the synthesis of 12beta-bromoacetoxy-4-estrene-3,17-dione and its use in affinity labeling of the enzyme. The steroid was synthesized by incubation of 4-estrene-3,17-dione with Colletotrichum gloesporioides. The product was recrystallized from ethanol and structure assured by IR and NMR spectroscopy. The steroid is a substrate, which indicates that it binds at the active site. When the enzyme is incubated with a 150-fold molar excess of 12beta-bromoacetoxy-4-estrene-3,17-dione in potassium phosphate buffer at pH 7.0, the enzyme is inactivated in a time-dependent, irreversible manner. Inactivation follows pseudo-first-order kinetics with a half life of 18 hours. Analysis of a hydrolysate of the enzyme after inactivation with 12beta-bromo[2'-3H]acetoxy-4-estrene-3,17-dione reveals tritiated 1-, 3-, and 1,3-dicarboxymethylhistidine. The affinity labeling of a histidyl enzyme residue by both 16alpha- and 12beta-bromoacetoxy steroids localizes that residue near the point of catalysis and suggests that it may participate in the catalytic event.

17-Hydroxysteroid Dehydrogenases↗
PubMed1976

Crystallization of human placental estradiol 17beta-dehydrogenase. A new method for crystallizing labile enzymes.

Estradiol 17beta-dehydrogenase from human placenta has been crystallized by a new technique, herein referred to as electrophoretic diffusion. This is the first crystallization of an enzyme from human placenta as well as the first crystallization of any steroid-converting enzyme of human source. A solution of the enzyme (specific activity 7.1 units/mg) in 1.5 ml of Tris-barbituric acid buffer, pH 7.0, containing 20% glycerol as stabilizer, was placed in an electrophoresis tube and the tube was closed at both ends with a dialysis membrane which permits the passage of substances of molecular weight less than 18,000. The tube was placed in a gel electrophoresis apparatus and the reservoirs filled with the Tris-barbituric acid buffer. A potential of 100 V was applied for 12 hours, then raised to 200 V for another 12 hours, and finally to 300 V until opalescence appeared at the bottom of the tube. Activity measurements showed that more than 90% of the enzyme had concentrated in the bottom 0.15-ml portion of the solution. When this section of the solution was removed and kept overnight at 4 degrees, gross and microscopic examination revealed a heavy crop of crystals which possessed a specific activity of 7.2 units/mg. The specific activity remained constant throughout three recrystallizations. The crystalline enzyme displayed a single band by analytical and sodium dodecyl sulfate-polyacrylamide gel analysis. Crystals of enzyme of high specific activity could also be obtained from an enzyme sample initially possessing a specific activity of only 4.5 units/mg. The new technique should be appliable for the crystallization of other labile enzymes and receptor proteins which have so far resisted crystallization by conventional methods.

Crystallization↗